Jiuzhou Pharmaceutical(SH:603456) Zheng Quan Zhi Xing·2025-06-11 10:28Core Viewpoint - The legal opinion letter from Zhejiang Tiance Law Firm confirms the legality and compliance of Zhejiang Jiuzhou Pharmaceutical Co., Ltd.'s differentiated equity distribution plan for the year 2024, ensuring that the interests of the company and all shareholders are not harmed [6][10]. Group 1: Differentiated Equity Distribution - The differentiated equity distribution is necessitated by the company's share repurchase plan, which involves using self-owned funds to buy back shares for future employee incentive plans [6][7]. - As of May 22, 2025, the total share capital of the company is 895,235,828 shares, with 13,525,800 shares held in the repurchase account, which will not participate in the profit distribution [6][7]. - The company plans to distribute a cash dividend of 3.00 yuan (including tax) for every 10 shares, totaling 265,760,198.40 yuan (including tax) to shareholders, excluding the shares in the repurchase account [6][7]. Group 2: Legal Compliance and Verification - The law firm has conducted thorough verification of the documents and materials provided by the company, ensuring their authenticity and completeness, and has adhered to legal responsibilities and principles of diligence and good faith [2][3]. - The law firm emphasizes that the legal opinion is limited to legal issues related to the differentiated equity distribution and does not cover accounting or auditing matters [3][4]. - The law firm concludes that the differentiated equity distribution complies with relevant laws and regulations, including the Company Law and Securities Law, and does not harm the interests of the company or its shareholders [10].